Japan’s Oncolys, Taiwan’s Medigen Team For Telomelysin Cancer Drug
This article was originally published in PharmAsia News
Japan's Oncolys BioPharma and the Taiwanese biotech Medigen Biotechnology have formed a partnership to develop Oncolys's Telomelysin cancer drug for Asian markets. The drug is a genetically modified form of the adenovirus that thrives only in cancer cells. Telomelysin is undergoing U.S. clinical trials as a treatment for tongue and esophageal cancers. Under the partnership, Medigen is to conduct Taiwan tests on the drug for treating liver cancer. (Click here for more - a subscription may be required
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.